



DURECT to Participate in Cowen and Company Healthcare Conference

CUPERTINO, Calif., March 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009 at 8:00 a.m. EDT. The conference is being held at the Marriott Hotel in Boston.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

03/09/2009

CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT Corporation, +1-408-777-4936

Photo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>
<http://photoarchive.ap.org>

PRN Photo Desk, photodesk@prnewswire.com

Web Site: <http://www.durect.com>